INBS

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth

Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units

Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year

502 active customers as of June 30, 2026, reflecting continued commercial momentum across safety-critical industries

Company made substantial progress toward FDA clearance and planned market expansion during the year

NEW YORK, August 19, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the full year ended June 30, 2026, and provided a business update.

“Fiscal 2026 was a year of clear, compounding progress across every aspect of our business,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “We delivered record annual revenue of $4.2 million, a 38% increase year-over-year, driven by a 22% expansion in our reader installed base and a 35% increase in consumable cartridges. Our razor-razorblade model is gaining scale, with hardware placements generating the installed base and growing consumable utilization delivering recurring revenue. Entering fiscal 2027, we are focused on three priorities: sustaining the operational improvements driving gross margin expansion, continuing to accelerate commercial growth, and advancing our FDA regulatory program toward planned U.S. market entry. To that end, we have completed all clinical data collection across our FDA 510(k) clinical study program. Analysis of collected data is underway, and we remain on track for our FDA submission.”

“The financial results for fiscal 2026 reflect a business that is scaling with improving unit economics,” said Spiro Sakiris, CFO at Intelligent Bio Solutions. “Full-year gross profit grew 64% to $2.05 million and gross margin expanded 778 basis points to 48.63%. These improvements are a result of our transition to Syrma Johari as a high-quality, lower-cost manufacturing partner, an optimized product mix weighted toward higher-margin cartridge consumables, and the operational leverage that comes from growing volumes across a more efficient production base. Our sustained investment in marketing, sales, product awareness, and customer support has been the direct commercial driver behind our 38% revenue growth and the expanding utilization we are seeing across our installed base.”

Full Year Fiscal 2026 Financial Highlights

●Total revenue of $4,215,175, up 38% year-over-year from $3,052,532.

●Revenue increase of $1,162,643 year-over-year.

●Gross profit of $2,049,994, up 64% year-over-year from $1,246,859.

●Gross profit margin of 48.63%, up from 40.85% - an improvement of 778 basis points.

●Reader installed base of 1,886 units as of June 30, 2026, up 22% from 1,545 units as of June 30, 2025.

●Total consumable cartridges of 106,500 units, up 35% from 78,750 in fiscal 2025.

●502 active customers as of June 30, 2026.

Progress Toward FDA Clearance and U.S. Market Expansion

INBS

made substantial progress throughout fiscal 2026 in advancing its FDA 510(k) submission, supporting its planned entry into the multi-billion-dollar U.S. drug screening market beyond current Forensic Use Only settings. The Company’s regulatory program accelerated significantly, underpinned by a series of clinical and technical studies:

●Initiated and completed a clinical cut-off study evaluating codeine detection cut-off levels in 40 adults, advancing the clinical evidence base for the 510(k) program.

●Completed penetration testing, with no major vulnerabilities identified, strengthening the cybersecurity component of the submission package.

●Initiated a multi-site method comparison study, designed to evaluate system accuracy when operated by intended end-users. The study was completed in early fiscal 2027.

●Initiated an interference study examining the impact of everyday substances on the Intelligent Fingerprinting Drug Screening System. The study was completed in early fiscal 2027.

●Initiated precision testing, evaluating reproducibility across varied manufacturing conditions and operating environments. The study was completed in early fiscal 2027, confirming reproducibility across more than 1,600 tests, three production runs, and three independent testing sites.

●Initiated a usability study designed to evaluate how effectively operators could be trained to use the Intelligent Fingerprinting Drug Screening System. The study was completed in early fiscal 2027.

●Initiated validation study for a rapid drug screening cartridge targeting 70% faster results.

●Strengthened the Company’s European intellectual property portfolio with its eighth paten

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year

Razor-razorblade

business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales

Nine-month

revenue reaches $3.07 million, up 39% year-over-year, building on record first-half performance

Gross profit margin expands to 50.5% in Q3 and 49.3% for the nine months, improving approximately 800 basis points year-over-year for the nine-month period

NEW YORK, May 13, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal third quarter and nine months ended March 31, 2026, and provided a business update.

“The third quarter marked another period of strong commercial execution and revenue growth,” said Harry Simeonidis, President and CEO at INBS. “Cartridge revenue increased 59% year-over-year and accounted for 66% of Q3 revenue, confirming that customer utilization patterns align with our recurring revenue, razor-razorblade business model. Nine-month revenue of $3.07 million reflects consistent and compounding growth, and the business is continuing to strengthen ahead of important FDA regulatory milestones and our anticipated entry into the multi-billion-dollar U.S. market.”

“Our results this quarter and over the past nine months demonstrate that we are delivering on our core business fundamentals,” said Spiro Sakiris, CFO at INBS. “Q3 gross margin was over 50%, up from 47% a year ago. This growth was driven by operational efficiencies and increased sales volumes. Our value-driven pricing structure has also remained consistent, as customers recognize the efficiency and cost-effectiveness of our fingerprint drug screening technology compared to traditional methods. Our nine-month marketing investment of $1.77 million has been a direct contributor to our 39% revenue growth and successful capital raising of $14.67 million (net of issuance costs), and we are now seeing improved marketing efficiency in Q3, with the quarter’s spend down 42% year-over-year while commercial momentum continues to accelerate.”

Product Revenue Breakdown

Three Months Ended March 31, 2026 (Q3 Fiscal 2026):

●Cartridge sales of $703,538, up 59% year-over-year, representing 66% of Q3 revenue

●Reader sales of $139,407, declined 16% year-over-year, reflecting normal quarterly variability following a strong Q2

●Other sales of $217,857, up 80% year-over-year, representing 21% of Q3 revenue

●Total revenue of $1.06 million, up 46% year-over-year

●Gross profit margin of 50.5%, up from 46.8% in the same period the year prior

●Cash and cash equivalents of $6.86 million at March 31, 2026, compared to $740,371 at December 31, 2025

Nine Months Ended March 31, 2026:

●Cartridge sales of $1.86 million, up 46% year-over-year, representing 61% of nine-month revenue

●Reader sales of $672,839, up 29% year-over-year

●Other sales of $535,942, up 31% year-over-year

●Total revenue of $3.07 million, up 39% year-over-year

●Gross profit margin of 49.3%, up from 41.3% in the same period the year prior

Fiscal Third Quarter and Nine Months Ended March 31, 2026, and Subsequent Highlights

●Gross margin exceeds 50%: Q3 gross profit margin of 50.47%, up from 46.84% in the prior year period, shows the Company’s ability to scale revenue while improving unit economics.

●Cartridge revenue up 59% year-over-year: Cartridge sales of $703,538 represented 66% of Q3 revenue, up from 61% a year ago. The installed base built through prior reader placements is now generating strong, recurring consumable demand.

●Nine-month revenue of $3.07 million: Building on the $2.01 million first-half milestone announced in February 2026, the Company added $1.06 million in revenue in Q3, demonstrating that commercial momentum is sustained and accelerating.

●Other sales surge 80% year-over-year: The 80% year-over-year growth in Q3 other sales signals a broadening product ecosystem and expanding revenue diversification beyond core hardware and consumables.

●FDA

510(k) regulatory program advancing: The Company continued to make progress on its planned entry into the multi-billion-dollar U.S. drug screening market, including successfully completing penetration testing with no major vulnerabilities identified, completing a clinical cut-off study, and initiating a validation study for the rapid drug screening cartridge targeting 70% faster results.

●New manufacturing partnership: The Company successfully manufactured and shipped its first readers under the new partnership, supporting improved margins and production scalability.

●Bouygues UK partnership: The Company announced a drug-testing rollout with Bouygues UK, part of the global construction group Bouygues Construction, adding a significant new customer in

false 0001725430

0001725430

2026-02-12 2026-02-12

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 12, 2026

INTELLIGENT

BIO SOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39825

82-1512711

(State of

Incorporation)

(Commission

File Number)

(IRS

employer

identification no.)

135 West, 41st Street, 5th Floor

New York, NY 10036

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (646) 828-8258

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value

INBS

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On February 12, 2026, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing financial results for the fiscal quarter ended December 31, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

No.

Description

99.1

Press release dated February 12, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 12, 2026

INTELLIGENT

BIO SOLUTIONS INC.

By:

/s/ Spiro Sakiris

Name:

Spiro Sakiris

Title: Chief Financial Officer